Elsevier

Clinical Breast Cancer

Volume 3, Issue 5, December 2002, Pages 333-340
Clinical Breast Cancer

Original Contribution
Phase II Trial of Doxorubicin/Docetaxel/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58

https://doi.org/10.3816/CBC.2002.n.036Get rights and content

Abstract

Based on the recommended phase II doses for doxorubicin (60 mg/m2) and docetaxel (60 mg/m2) and the National Surgical Adjuvant Breast and Bowel Project's (NSABP) experience with doxorubicin and cyclophosphamide (cyclophosphamide 600 mg/m2), we conducted a phase II trial at 18 institutions using doxorubicin/docetaxel/cyclophosphamide (ATC) given every 21 days, in preparation for a major adjuvant breast cancer study (NSABP B- 30), in which ATC would be used. Eligibility requirements included measurable stage IIIB/IV breast cancer, performance status 0-2, normal left ventricular ejection fraction, and no prior chemotherapy for metastatic disease (nontaxane adjuvant chemotherapy was allowed if completed > 12 months before entry and if the cumulative dose of doxorubicin was ≤ 240 mg/m2). Eighty-nine patients were entered who ranged in age from 30-78 years (38.2% < 50 years; 61.8% ≥ 50 years). A total of 33.7% of patients had stage IIIB disease, and 66.3% had stage IV disease. Among the stage IV patients, 20.3% had received prior adjuvant chemotherapy. Dexamethasone premedication (8 mg p.o. b.i.d. for 3 days) and prophylactic ciprofloxacin (500 mg p.o. b.i.d. days 5-15) were used. Colony-stimulating growth factors were reserved for secondary prophylaxis after prolonged or febrile neutropenia (FN) or documented severe infection in a prior cycle. After a cumulative dose of doxorubicin 480 mg/m2, patients could continue with docetaxel/cyclophosphamide alone. Eighty-nine patients and 577 courses were evaluable for toxicity. Median time on study as of May 2002 was 36.5 months (range, 28–47 months). Febrile neutropenia occurred in 34 patients (38%); 8 developed FN in the absence of prior prophylactic growth factor support; 26 developed FN despite prior growth factor support (for one patient this information was unavailable). There were no septic deaths. One patient died from pulmonary embolism. Other grade 3/4 adverse events included: nausea (9%), vomiting (7%), stomatitis (6%), diarrhea (4%), arthralgia/myalgia (3%), and neurotoxicity (1%). Clinical congestive heart failure was seen in 3 patients (3.4%). Seventy-seven patients were evaluable for best response within 6 cycles of therapy. Thirteen patients (16.9%) had a complete response, 43 (55.8%) had a partial response, for an overall response rate of 72.7%. The median response duration was 23.8 months (95% CI, 16.2-37.8 months), and the median time to progression or death was 23.5 months (95% CI, 16.3-38.7 months). The median survival time was 35.6 months (95% CI, 26.6-39.4 months). The administration of ATC with primary ciprofloxacin and secondary colony-stimulating factor prophylaxis is feasible and active. Its value in the adjuvant setting is currently under investigation.

References (31)

  • V Valero et al.

    Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

    J Clin Oncol

    (1995)
  • S Chan et al.

    Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group

    J Clin Oncol

    (1999)
  • IC Henderson et al.

    Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)

    Proc Am Soc Clin Oncol

    (1998)
  • Henderson IC. 2000 NIH Consensus Development Conference on Adjuvant Breast Cancer Treatment; November 1-3, 2000;...
  • Mamounas EP. 2000 NIH Consensus Development Conference on Adjuvant Breast Cancer Treatment; November 1-3, 2000;...
  • Cited by (20)

    • MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer

      2017, Clinical Breast Cancer
      Citation Excerpt :

      The taxanes have substantial activity against breast cancer, even after failed treatment with anthracyclines.7 However, the treatment with this regimen presents several adverse effects, including nausea, vomiting, low white blood cell counts, cardiotoxicity, fever, diarrhea, and peripheral neuropathy.8,9 Currently, there are no clinically useful predictive markers to identify patients who are likely to respond to taxanes.10

    • Chemotherapy Protocols and Infusion Sequence: Schedule Consideration in Cancer Treatment

      2022, Chemotherapy Protocols and Infusion Sequence: Schedule Consideration in Cancer Treatment
    View all citing articles on Scopus
    View full text